PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsDimenhydrinate
Dimenhydrinate
Dimenhydrinate (dimenhydrinate) is a small molecule pharmaceutical. Dimenhydrinate was first approved as Dimenhydrinate on 1982-01-01. It is used to treat motion sickness, nausea, vertigo, and vomiting in the USA.
Download report
Favorite
Top OTC Drugs
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
otorhinolaryngologic diseasesD010038
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
airmit aceC2002632023-12-01
dimenhydrinateC2002632024-01-23
dramamineOTC monograph final2023-03-15
dramamine - nOTC monograph final2019-02-25
dramamine for kidsOTC monograph final2021-04-09
dramamine less drowsyOTC monograph final2019-02-19
dramamine orangeOTC monograph final2017-12-06
dramamine original formulaC2002632023-12-27
driminateC2002632023-04-18
gravolOTC monograph final2022-03-07
Show 3 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
motion sicknessD009041T75.3
nauseaHP_0002018D009325R11.0
vertigoD014717H81.39
vomitingHP_0002013D014839R11.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
R: Respiratory system drugs
R06: Antihistamines for systemic use
R06A: Antihistamines for systemic use
R06AA: Aminoalkyl ethers, systemic antihistamines
R06AA11: Dimenhydrinate
R06AA61: Dimenhydrinate, combinations
HCPCS
Code
Description
J1240
Injection, dimenhydrinate, up to 50 mg
Clinical
Clinical Trials
128 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C501124
Postoperative nausea and vomitingD020250EFO_00048881113
VertigoD014717H81.39123
Dry eye syndromesD015352H04.12123
Knee osteoarthritisD020370EFO_0004616M17112
VomitingD014839HP_0002013R11.1112
NauseaD009325HP_0002018R11.0112
PainD010146EFO_0003843R5211
Postoperative painD010149G89.1811
Diabetes complicationsD04890911
Show 8 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
BronchiectasisD001987HP_0002110J47112
Metabolic syndromeD024821EFO_0000195E88.810112
Eczematous skin diseasesD017443111
Athletic injuriesD001265111
Pain managementD05940811
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients212
ObesityD009765EFO_0001073E66.9112
Spinal stenosisD013130EFO_0007490M48.01112
Multiple myelomaD009101C90.011
Drug eruptionsD003875111
AcromegalyD00017211
B-cell chronic lymphocytic leukemiaD015451C91.1111
B-cell lymphomaD016393111
Q feverD011778EFO_0005224A7811
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CicatrixD002921HP_0100699L90.5123
Atopic dermatitisD003876EFO_0000274L2011
Rheumatoid arthritisD001172EFO_0000685M06.911
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8044
DehydrationD003681E86.044
Positron emission tomography computed tomographyD00007207822
XerostomiaD014987K11.722
Chronic renal insufficiencyD051436N1822
Gingival recessionD005889K06.022
Ocular hypertensionD009798EFO_1001069H40.011
Acne vulgarisD000152EFO_0003894L7011
Neuroendocrine tumorsD018358EFO_1001901D3A.811
OsteomalaciaD010018EFO_1002027M8311
Show 40 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDimenhydrinate
INNdimenhydrinate
Description
8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine is a diarylmethane.
Classification
Small molecule
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2[nH]c(Cl)nc2n(C)c1=O
Identifiers
PDB
CAS-ID523-87-5
RxCUI
ChEMBL IDCHEMBL1200406
ChEBI ID
PubChem CID10660
DrugBankDB00985
UNII IDJB937PER5C (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
No data
Estimated US medical usage
Dimenhydrinate
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,571 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,337 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use